Cipla
CIPLA • Pharmaceuticals & Biotechnology
Last Price
₹1358.00
Market Cap
₹1.10L Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-09-1618% below its 52-week high
Price trend
Neutral
Over the last 6 months, Cipla's share price has risen, doing better than 24% of Pharmaceuticals & Biotechnology stocks.
Institutional activity
Positive
Trading patterns over recent weeks show some signs of institutions buying Cipla (buying score 3/10, selling score 1/10).
Model rank
Neutral
Our model's 5-day return score puts Cipla ahead of 42% of NSE stocks. The model has low confidence in this score (16%).
Ease of trading
Low
Shares change hands easily; there are no signs of trading drying up (risk score 2/10).
Price vs profits
Typical
The share price is 28× last year's profit per share — about in the typical range for NSE stocks (15–30×).
The wider Indian market is in a downtrend (model 100% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Cipla (CIPLA)
Cipla is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE059A01026). This page brings together the quantitative research signals our models compute for CIPLA: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Cipla's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.